Treatment regimen for hormone-sensitive cancers

Details Treatment regimen for hormone-sensitive cancers Treatment regimen for hormone-sensitive cancers

A - Human Necessities

61

P

A61P 35/00 (2006.01) A61K 31/565 (2006.01) A61K 31/70 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2366697

This invention provides for a novel schedule and dosage regimen of the combination paclitaxel-estramustine and chemical or surgical hormone depletion to treat patients with advanced breast cancer who have not received previous therapy and are candidates for hormonal therapy. This invention differs from all current treatment strategies by the intercalation of cytotoxic chemotherapy (preferably paclitaxel and estramustine) at a specified interval (two months; range 2 weeks to 6 months) after initiation of hormone depletion therapy.

Cette invention concerne un régime à programme et à dosage se servant de la combinaison paclitaxel-estramustine et de la déplétion chimique ou chirurgicale hormonale pour traiter des patients atteints d'un cancer du sein avancé, qui n'ont préalablement pas suivi d'autre thérapie et se portent volontaires pour une thérapie hormonale. Cette invention se distingue des stratégies de traitement adoptées actuellement par l'interposition d'une chimiothérapie cytotoxique (de préférence au moyen de paclitaxel et d'estramustine) à intervalles réguliers (2 mois; de deux semaines à 6 mois) après le début de la thérapie par déplétion hormonale.

Affiliated with

Also associated with

Rating

Treatment regimen for hormone-sensitive cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment regimen for hormone-sensitive cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment regimen for hormone-sensitive cancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1982705